Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

NCT00087269 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

110

Enrollment

NIH

Sponsor class

Conditions

Stage IA Non-small Cell Lung Cancer
Stage IB Non-small Cell Lung Cancer
Stage IIA Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer

Interventions

DRUG: erlotinib hydrochloride
PROCEDURE: therapeutic endoscopic surgery
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)